(NASDAQ: INCY) Incyte's forecast annual revenue growth rate of 8.51% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.71%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.87%.
Incyte's revenue in 2025 is $4,584,996,000.On average, 9 Wall Street analysts forecast INCY's revenue for 2025 to be $945,134,198,486, with the lowest INCY revenue forecast at $909,951,685,994, and the highest INCY revenue forecast at $964,365,383,798. On average, 9 Wall Street analysts forecast INCY's revenue for 2026 to be $1,046,844,754,990, with the lowest INCY revenue forecast at $997,757,409,317, and the highest INCY revenue forecast at $1,115,807,892,530.
In 2027, INCY is forecast to generate $1,142,831,572,408 in revenue, with the lowest revenue forecast at $1,039,993,881,995 and the highest revenue forecast at $1,286,899,086,972.